Health
Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis
We believe regulatory strategy expedites development of potential first treatment to address DLB psychosisPURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of fina
About this update from Cognition Therapeutics, Inc.
[{"type":"image","alt":"Cognition Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cognition Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3G97CJjBroOGRUYevL.t.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22","width":250,"height":70}},"lazy":false},{"type":"text","content":"We believe regulatory strategy expedites development of potential first treatment to address DLB psychosis","length":106,"tagName":"p"},{"type":"text","content":"PURCHASE, N.Y., March 02, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced plans to advance development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which impacts as many as 75% of patients. This follows receipt of final minutes from the U.S. Food and Drug Administration (FDA) pertaining to the Type C meeting that was conducted on January 21, 2026.","length":525,"tagName":"p"},{"type":"text","content":"“Based on the Agency’s meeting minutes and the strength of our Phase 2 ‘SHIMMER’ data in the psychiatric and behavioral domain, we believe the best strategy is to pursue a registrational path for the treatment of DLB psychosis,” explained Anthony O. Caggiano, MD, PhD, Cognition’s CMO. “Symptoms of DLB psychosis are reported to be extremely debilitating and often lead to institutionalization. Since DLB patients are unable to tolerate many antipsychotic medications, there is a need for treatments developed for this specific population. We believe that zervimesine has the potential to make a meaningful difference in the lives of DLB patients and their families.”","length":667,"tagName":"p"},{"type":"text","content":"As planned, the next study for DLB will focus on the measurement of neuropsychiatric symptoms such as hallucinations and delusions, and behavioral symptoms such as anxiety, aggression, and agitation. We expect symptoms will be measured using established validated endpoints. Participants will be randomized to either 100mg of oral zervimesine or placebo dail...